Azacitidine
Injection · trading as Vidaza
Current Active — Day 1973
FDA shortage record
- Substance
- Azacitidine
- Brand name
- Vidaza
- Manufacturers / suppliers
-
- Celgene Corporation
- Bristol Myers Squibb Co.
- Dosage form
- Injection
- Presentation
- Vidaza, Injection, 100 mg (NDC 59572-102-01)
- Route(s)
- INTRAVENOUS, SUBCUTANEOUS
- Therapeutic category
- Oncology
- Package NDC
59572-102-01- Initially posted
- 12/18/2020
- Days on shortage list
- 1973
- Current FDA status
- Current
- Shortage entries (current dataset)
- 2 records for Azacitidine
Why this shortage matters
Oncology drugs treat cancers including solid tumors, leukemia, and lymphoma. Shortages of chemotherapy agents can delay or interrupt regimens where dose timing and intensity directly affect treatment outcomes.
FDA therapeutic class: Oncology
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 1-888-423-5436.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
3495a71a-cc04-4776-851f-f185956f32af). - FDA UNII identifier:
M801H13NRU. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.